Biopharmaceutical companies continue to seek growth opportunities amidst increased focus on specialty pharmaceuticals. Increasing investment across the industry has been seen in scientific innovation (Immuno-oncology, Immunology), rare diseases, precision medicine, new technologies (ADCs, BsAbs, Cell & Gene Therapy), translational medicine and AI- driven drug discovery.
The Biopharmaceutical and MedTech M&A landscapes are shaped by investment cycles, based on macroeconomic factors. However, deal activity continues to drive innovation for new products and operational performance improvement.
Our team brings significant operating and consulting experience across the Biopharmaceutical, MedTech and Private Equity sectors. We advise and partner with clients to assist them in achieving their goals, and performance improvement across the investment continuum from strategy through operational implementation.
We can help with:
We assist various Life Science companies and their investors, including:
- Biopharmaceutical Companies
- MedTech Companies (Devices and Diagnostics)
- Pharmaceutical Services Organizations (CMOs, CDMOs, CROs)
- Board of Directors
- PE Firms
- Activist Investors
- Law Firms (Restructuring, Bankruptcy, Disputes & Investigations, Expert Witness Reports and Testimony)
- Unsecured Creditor Committees
Medical Device Supply Chains: Disruption Is Permanent. Is the Industry Ready?
June 18, 2026
Medical device supply chains are under increasing pressure as global disruption becomes a constant rather than an exception. From geopolitical volatility to material scarcity and regulatory complexity, the sector now operates in an environment where even minor shocks can have far-reaching consequences. This article explores the structural vulnerabilities shaping today’s MedTech supply networks and highlights why traditional approaches are no longer sufficient. It outlines how leading organisations are rethinking resilience not just as risk mitigation, but as a source of competitive advantage in an increasingly unpredictable world. Download the full article to uncover the strategies that are helping companies respond faster, protect patient outcomes, and maintain operational continuity.
The DTP Portfolio Test: A Decision Framework for Direct-to-Patient Investment by Pharma
June 15, 2026
The DTP Portfolio Test: A Decision Framework for Direct-to-Patient Investment by Pharma
Q4 | 2025 NAVIGATING DEALFLOW: EUROPEAN SOFTWARE QUARTERLY
March 19, 2026
After years of rising growth multiples, Europe’s software market is repricing. Our first Navigating Dealflow: European Software Quarterly brings a clear view of how this reset is changing M&A, where valuations are landing, and which segments are holding up.
CDMO platforms will be the central arena for MedTech M&A in 2026
February 19, 2026
The MedTech manufacturing landscape is entering a pivotal phase.
